![James Anthony Cook](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
James Anthony Cook has worked in various jobs throughout his career.
His current job is as the Chairman of Zetta Genomics Ltd.
Aktive Positionen von James Anthony Cook
Unternehmen | Position | Beginn |
---|---|---|
Zetta Genomics Ltd.
![]() Zetta Genomics Ltd. Data Processing ServicesTechnology Services Zetta Genomics Ltd. is a British company that focuses on the potential of genomic data to transform research discovery, clinical diagnosis, and the effective application of precision medicine. The company is based in Cambridge, UK, and was founded in 2018. Zetta Genomics is a spin-out from two genomic data pioneers, the University of Cambridge and Genomics England. The company's team is highly talented and diverse, and they explore new and innovative approaches to transforming the future of precision medicine. The company uses a uniquely 'genomic native' technology built on the open-source opencb platform, and their development is led by opencb's chief. The company's goal is to unleash the power of genomic data to improve health outcomes for millions of patients around the world and realize the potential of precision medicine. The CEO is William Spooner. | Vorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Zetta Genomics Ltd.
![]() Zetta Genomics Ltd. Data Processing ServicesTechnology Services Zetta Genomics Ltd. is a British company that focuses on the potential of genomic data to transform research discovery, clinical diagnosis, and the effective application of precision medicine. The company is based in Cambridge, UK, and was founded in 2018. Zetta Genomics is a spin-out from two genomic data pioneers, the University of Cambridge and Genomics England. The company's team is highly talented and diverse, and they explore new and innovative approaches to transforming the future of precision medicine. The company uses a uniquely 'genomic native' technology built on the open-source opencb platform, and their development is led by opencb's chief. The company's goal is to unleash the power of genomic data to improve health outcomes for millions of patients around the world and realize the potential of precision medicine. The CEO is William Spooner. | Technology Services |